Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018:60:e25.
doi: 10.1590/s1678-9946201860025. Epub 2018 Jun 28.

The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori

Affiliations

The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori

Júlia Silveira Vianna et al. Rev Inst Med Trop Sao Paulo. 2018.

Abstract

In this study, we evaluated the mutations of Helicobacter pylori associated with resistance to clarithromycin and levofloxacin. Furthermore, based on the proposed interaction between antimicrobial resistance and pathogenicity, we correlated the mutation profiles of the strains with the presence of the pathogenicity gene cagA. We analyzed 80 gastric biopsy specimens from H. pylori-infected patients for point mutations in the 23S rRNA gene region and in the gyrA gene, which are related to clarithromycin and levofloxacin resistance, respectively, and investigated the presence of the cagA gene in these strains. We observed that in the assayed biopsies, 8.7% (7/80) had mutations in the 23S rRNA gene region at positions 2143 and 2142, while 22.5% (18/80) had mutations in gyrA at codons 87 and 91. Moreover, absence of the CagA-EPIYA pathogenicity factor was observed in 68% (17/25) of resistant samples. The knowledge of the local profile of antimicrobial resistance and the complex interplay involving resistance and pathogenicity can contribute to an appropriate clinical approach.

PubMed Disclaimer

References

    1. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30. - PubMed
    1. Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of CLA resistance. J Antimicrob Chemother. 1997;40:283–286. - PubMed
    1. Wang LH, Cheng H, Hu FL, Li J. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol. 2010;16:2272–2277. - PMC - PubMed
    1. Agudo S, Pérez-Pérez G, Alarcón T, López-Brea M. High prevalence of CLA-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol. 2010;48:3703–3707. - PMC - PubMed
    1. Vianna JS, Ramis IB, Ramos DF, Von Groll A, Silva PE. Drug resistance in Helicobacter pylori. Arq Gastroenterol. 2016;53:215–223. - PubMed

MeSH terms